Eukaryotic Initiation Factor (eIF)

eIF4A3-IN-12 is an eIF4F inhibitor, specifically disrupting the assembly of the eIF4F translation complex. With EC50 values of 4 nM for myc-LUC, 70 nM for tub-LUC, and 5 nM for inhibiting the growth of MBA-MB-231 cells, this compound demonstrates potent biological activity. eIF4A3-IN-12 is valuable for investigating human cancer pathogenesis and understanding the role of translation regulation in tumorigenesis.

(R)-eIF4A3-IN-2 is the less active enantiomer of eIF4A3-IN-2, a selective noncompetitive inhibitor of eukaryotic initiation factor 4A-3 (eIF4A3). With an IC50 of 110 nM, eIF4A3-IN-2 demonstrates significant inhibition of eIF4A3, impacting mRNA splicing and translation processes. This compound is useful in research applications focused on cancer biology, novel therapeutic pathways, and the regulation of gene expression.

eIF4A3-IN-16 is a potent eIF4F inhibitor that selectively disrupts the assembly of the eIF4F translation complex. It demonstrates significant biological activity, inhibiting MBA-MB-231 cell growth with an EC50 of 1 nM. Additionally, eIF4A3-IN-16 affects myc-LUC and tub-LUC with EC50 values of 1 nM and 30 nM, respectively. This compound is applicable in research focused on triple negative breast cancer (TNBC).

Fosigotifator THAM sodium is a potent activator of eukaryotic initiation factor 2B (EIF2B), enhancing its stability and function. This compound is capable of penetrating the blood-brain barrier and demonstrates efficacy in boosting EIF2B activity, particularly in scenarios involving pathogenic vanishing white matter (VWM) mutations. As an integrated stress response inhibitor, Fosigotifator THAM sodium serves as a valuable tool in research focused on amyotrophic lateral sclerosis and related neurodegenerative conditions.

eIF4E-IN-3 is a highly effective inhibitor of eukaryotic initiation factor 4E (eIF4E), a critical component in the protein synthesis initiation pathway. This compound demonstrates significant potential in investigating eIF4E-dependent diseases, particularly in cancer research. By modulating eIF4E activity, eIF4E-IN-3 offers valuable insights into the molecular mechanisms underlying tumorigenesis and may aid in the development of targeted therapeutic strategies.

eIF4A3-IN-15 is a targeted inhibitor of the eIF4F translation complex, effectively disrupting its assembly. This compound demonstrates potent activity with EC50 values of 11, 700, and 120 nM against myc-LUC and tub-LUC, as well as growth inhibition in MBA-MB-231 cancer cells. eIF4A3-IN-15 is suitable for research applications focused on understanding the mechanisms underlying human cancer pathogenesis.

eIF4A3-IN-9 is a potent eIF4F inhibitor that disrupts the formation of the eIF4F translation complex. Demonstrating EC50 values of 29 nM for myc-LUC, 450 nM for tub-LUC, and an effective growth inhibition in MBA-MB-231 cells, this compound serves as a valuable tool in the study of cancer biology. Its targeted action makes it suitable for investigating human cancer pathogenesis and exploring therapeutic strategies against malignancies.

eIF4A3-IN-4 is a selective inhibitor of the eIF4A protein, exhibiting an IC50 value of 8.6 μM. This compound is relevant for research applications targeting the regulation of translation initiation and the modulation of gene expression. It has potential utility in studying cancer biology and other disorders related to abnormal protein synthesis.

eIF4A3-IN-10 is an inhibitor of the eIF4F translation complex. It exhibits significant biological activity, with EC50 values of 35 nM for myc-LUC and 100 nM for growth inhibition in MBA-MB-231 cancer cells. This compound serves as a valuable tool in researching the pathogenesis of human cancers, particularly in the context of disrupted translation regulation associated with tumorigenesis.

eIF4A3-IN-17 is an eIF4F inhibitor that disrupts the assembly of the eIF4F translation complex. It has demonstrated potent biological activity with EC50 values of 0.9 nM for myc-LUC, 15 nM for tub-LUC, and 1.8 nM for inhibiting the growth of MBA-MB-231 cells. This compound can be utilized in research focused on understanding human cancer pathogenesis and the mechanisms underlying oncogenic translation regulation.

eIF4A3-IN-13 is an inhibitor of the eIF4F translation complex, functioning through disruption of its assembly. This compound exhibits potent biological activity, with EC50 values of 0.6 nM for myc-LUC, 15 nM for tub-LUC, and 0.4 nM for growth inhibition in MBA-MB-231 breast cancer cells. eIF4A3-IN-13 is a valuable tool for investigating the mechanisms of human cancer pathogenesis and exploring therapeutic strategies targeting translation regulation.

eIF4A3-IN-11 is a potent inhibitor of the eIF4F translation complex. It effectively disrupts complex assembly, exhibiting EC50 values of 0.2 nM for myc-Luciferase, 4 nM for tubulin-Luciferase, and 0.3 nM for the inhibition of MBA-MB-231 cancer cell growth. This compound is valuable for investigating the molecular mechanisms underlying human cancer pathogenesis.

eIF4A3-IN-14 is a selective inhibitor of eIF4A, a crucial component of the eIF4F translation complex. This compound demonstrates potent inhibitory activity with an EC50 of approximately 40 nM against myc-LUC and over 2000 nM against tub-LUC. eIF4A3-IN-14 is valuable for investigating tumorigenesis and the molecular mechanisms of translational regulation in cancer research.

CMLD012612 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), designed to disrupt the translation initiation process in eukaryotic cells. This amidino-rocaglate compound features a hydroxamate group, demonstrating significant cytotoxicity in NIH/3T3 cells, with an IC50 value of 2 nM. By modifying the activity of the RNA helicase eIF4A, CMLD012612 exhibits promising anti-neoplastic properties, making it a valuable tool for cancer research and studies focused on translation regulation.

Fosigotifator is an orally active activator of eukaryotic initiation factor 2B (eIF2B), known for its ability to penetrate the blood-brain barrier. By stabilizing the eIF2B complex, Fosigotifator enhances its activity, particularly in the context of pathogenic vanishing white matter (VWM) mutations. As an integrated stress response inhibitor (ISRI), this compound is valuable for research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).

CMLD012073 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), functioning through the mechanism of amidino-rocaglates. This compound effectively inhibits cell growth in NIH/3T3 cells with an IC50 value of 10 nM. CMLD012073 disrupts eukaryotic translation initiation by altering the activity of the RNA helicase eIF4A, making it a valuable tool for research applications related to protein synthesis and gene regulation.

CMLD012072 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4A1 and eIF4A2 through RNA clamping. This amidino-rocaglate compound exhibits significant anti-neoplastic activity, making it a valuable tool for researching the role of eIF4A in cancer biology and therapeutic interventions. Its mechanism of action provides insight into the regulation of protein synthesis in neoplastic cells, facilitating further studies in oncology and molecular biology.

eIF4A3-IN-7 is a potent inhibitor of the eIF4A3 protein, a key regulator of mRNA translation and splicing. This compound demonstrates significant potential for research in cancer and other dysproliferative diseases by modulating gene expression pathways. Its targeted mechanism of action may provide valuable insights into the role of eIF4A3 in tumorigenesis and other pathological conditions.

1,3-Bis[3,5-bis(trifluoromethyl)phenyl]urea is a potent activator of the eIF2α kinase heme-regulated inhibitor. It effectively reduces the levels of the eIF2·GTP·tRNAiMet ternary complex, thereby modulating protein synthesis. This compound also demonstrates significant inhibitory effects on cancer cell proliferation, making it a valuable tool in cancer research and investigations into cellular stress responses.